Sotalol detailed information: Difference between revisions
m (Protected "Sotalol detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 21: | Line 21: | ||
{{CMG}} | {{CMG}} | ||
==[[Sotalol (patient information)|For patient information, click here]]== | ==[[Sotalol (patient information)|For patient information, click here]]== | ||
Revision as of 16:10, 20 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | >95% |
| Metabolism | Not metabolised |
| Elimination half-life | 12 hours |
| Excretion | Renal Lactic (In lactating females) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H20N2O3S |
| Molar mass | 272.3624 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.
Pharmacology
It falls into the class III antiarrhythmic agents because it inhibits the inward potassium ion channels in the heart. It is also a beta blocker because of its primary action on the β-adrenergic receptors in the heart.
By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.
It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).
Sotalol is a racemic mix of D and L enantiomers. The L isomer is a beta blocker.
Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
Indications
Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.
Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.[1]
Footnotes
- ↑ Waldo A, Camm A, deRuyter H, Friedman P, MacNeil D, Pauls J, Pitt B, Pratt C, Schwartz P, Veltri E (1996). "Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol". Lancet. 348 (9019): 7–12. PMID 8691967.
See also
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antiarrhythmic agents
- Beta blockers
- Drugs